Anacor Pharmaceuticals (ANAC)
Add to Watchlists Create an Alert
5.47
-0.02 -0.36%
NASDAQ
May 23, 8:00PM
BATS Real time
Currency in USD
Anacor Pharmaceuticals Revenue Quarterly YoY Growth:
26.66% for Dec. 31, 2012Anacor Pharmaceuticals Historical Revenue Quarterly YoY Growth Data
Pro Data Export
Dates:
to
There is no data for the selected date range.
| Data for this Date Range | |
|---|---|
| Dec. 31, 2012 | 26.66% |
| Sept. 30, 2012 | -80.44% |
| June 30, 2012 | -10.33% |
| March 31, 2012 | 9.42% |
| Dec. 31, 2011 | -26.73% |
| Sept. 30, 2011 | -25.17% |
| June 30, 2011 | -57.19% |
| March 31, 2011 | 211.1% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
ANAC Revenue Quarterly YoY Growth Benchmarks
| Companies | |
|---|---|
| Valeant Pharmaceuticals International | 24.79% |
| QLT | |
| Santarus | 73.15% |
ANAC Revenue Quarterly YoY Growth Rankings
| Overall |
90th percentile 750 of 8006 |
| Sector |
82nd percentile 119 of 686 in Healthcare |
| Industry |
79th percentile 51 of 248 in Biotechnology |
ANAC Revenue Quarterly YoY Growth Range, Past 5 Years
| Minimum | -80.44% | Sep 2012 |
| Maximum | 1938% | Sep 2010 |
| Average | 193.8% |
ANAC News
Anacor Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Seeking Alpha May 10
Seeking Alpha May 10